导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.04% | 3978/4773 |
| 近一周 | -3.37% | 4118/5462 |
| 近一月 | -3.39% | 1731/5421 |
| 近一季 | -1.93% | 1101/5209 |
| 近半年 | -5.26% | 2803/4920 |
| 近一年 | -16.39% | 3785/4366 |
| 近两年 | 30.74% | 2239/2954 |
| 近三年 | 10.68% | 1729/2253 |
| 成立以来 | 27.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-15.07% 4692/4961 |
9.49% 2483/5312 |
- - |
- - |
| 2025 | 4.38% 3052/4813 |
-6.76% 3394/3635 |
4.57% 733/4076 |
11.53% 3152/4524 |
-4.01% 3377/4813 |
| 2024 | 28.77% 147/3463 |
-4.86% 1785/2808 |
-8.58% 2251/3014 |
43.18% 16/3129 |
3.41% 825/3463 |
| 2023 | 4.81% 214/2656 |
4.30% 991/2280 |
-2.60% 617/2385 |
7.86% 23/2515 |
-4.35% 977/2655 |
| 2022 | -25.52% 1323/2207 |
-18.52% 1350/1919 |
2.16% 1337/2016 |
-15.95% 1376/2113 |
6.45% 363/2208 |
| 2021 | -0.42% 752/1822 |
-14.34% 1173/1255 |
8.32% 635/1330 |
5.31% 281/1466 |
1.91% 756/1822 |
| 2020 | 24.48% 633/1250 |
-9.97% 735/1028 |
11.23% 741/1067 |
21.41% 41/1164 |
2.38% 993/1184 |
| 2019 | - - |
- - |
- - |
- - |
10.52% 125/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证全指证券公司ETF VS. 长安沪深300非周期A(740101) |